Home / Investors / Overview

Company Information

CymaBay Therapeutics (Nasdaq: CBAY)

We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. We are evaluating seladelpar in primary biliary cholangitis (PBC). We also have two product programs in earlier development that feature unique mechanisms of action and have potential in liver and chronic diseases.

Stock Information

Last Change Volume

Shares Outstanding: 10,064,495
(as of March 3, 2014)

Company Information

CymaBay Therapeutics
7575 Gateway Blvd
Suite 110
Newark, CA 94560

Investor Relations

LifeSci Advisors, LLC
Hans Vitzthum
(617) 430-7578

Recent News


CymaBay Appoints Thomas Wiggans and Janet Dorling to Board of Directors


CymaBay Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update


CymaBay Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 25, 2021

Upcoming Event

Jun 10 2021 8:00 AM PT

2021 Annual Meeting of Stockholders

June 10, 2021 at 8:00 AM PT

Virtual Meeting

Meeting Link:

Q4 2020 Quarterly Results